298 related articles for article (PubMed ID: 21447005)
21. Mutation of FAS, XIAP, and UNC13D genes in a patient with a complex lymphoproliferative phenotype.
Boggio E; Aricò M; Melensi M; Dianzani I; Ramenghi U; Dianzani U; Chiocchetti A
Pediatrics; 2013 Oct; 132(4):e1052-8. PubMed ID: 24043286
[TBL] [Abstract][Full Text] [Related]
22. Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a new germline Fas gene mutation.
Del-Rey MJ; Manzanares J; Bosque A; Aguiló JI; Gómez-Rial J; Roldan E; Serrano A; Anel A; Paz-Artal E; Allende LM
Immunobiology; 2007; 212(2):73-83. PubMed ID: 17336828
[TBL] [Abstract][Full Text] [Related]
23. Differential regulation of miR-146a/FAS and miR-21/FASLG axes in autoimmune lymphoproliferative syndrome due to FAS mutation (ALPS-FAS).
Marega LF; Teocchi MA; Dos Santos Vilela MM
Clin Exp Immunol; 2016 Aug; 185(2):148-53. PubMed ID: 27060458
[TBL] [Abstract][Full Text] [Related]
24. [Autoimmune lymphoproliferative syndrome: an inherited or a somatic defect of apoptosis].
Rieux-Laucat F
Med Sci (Paris); 2006; 22(6-7):645-50. PubMed ID: 16828042
[TBL] [Abstract][Full Text] [Related]
25. Study of the potential role of CASPASE-10 mutations in the development of autoimmune lymphoproliferative syndrome.
Consonni F; Moreno S; Vinuales Colell B; Stolzenberg MC; Fernandes A; Parisot M; Masson C; Neveux N; Rosain J; Bamberger S; Vigue MG; Malphettes M; Quartier P; Picard C; Rieux-Laucat F; Magerus A
Cell Death Dis; 2024 May; 15(5):315. PubMed ID: 38704374
[TBL] [Abstract][Full Text] [Related]
26. Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humoral autoimmunity.
Fuss IJ; Strober W; Dale JK; Fritz S; Pearlstein GR; Puck JM; Lenardo MJ; Straus SE
J Immunol; 1997 Feb; 158(4):1912-8. PubMed ID: 9029133
[TBL] [Abstract][Full Text] [Related]
27. Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.
López-Nevado M; González-Granado LI; Ruiz-García R; Pleguezuelo D; Cabrera-Marante O; Salmón N; Blanco-Lobo P; Domínguez-Pinilla N; Rodríguez-Pena R; Sebastián E; Cruz-Rojo J; Olbrich P; Ruiz-Contreras J; Paz-Artal E; Neth O; Allende LM
Front Immunol; 2021; 12():671755. PubMed ID: 34447369
[TBL] [Abstract][Full Text] [Related]
28. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity.
Drappa J; Vaishnaw AK; Sullivan KE; Chu JL; Elkon KB
N Engl J Med; 1996 Nov; 335(22):1643-9. PubMed ID: 8929361
[TBL] [Abstract][Full Text] [Related]
29. Accessory spleen: differential diagnosis for lymphoma in autoimmune lymphoproliferative syndrome.
Georgin-Lavialle S; Aouba A; Canioni D; Rieux-Laucat F; Fischer A; Hermine O
Pediatr Blood Cancer; 2010 Jul; 54(7):1020-2. PubMed ID: 20162683
[TBL] [Abstract][Full Text] [Related]
30. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency.
Chun HJ; Zheng L; Ahmad M; Wang J; Speirs CK; Siegel RM; Dale JK; Puck J; Davis J; Hall CG; Skoda-Smith S; Atkinson TP; Straus SE; Lenardo MJ
Nature; 2002 Sep; 419(6905):395-9. PubMed ID: 12353035
[TBL] [Abstract][Full Text] [Related]
31. Understanding the Spectrum of Immune Dysregulation Manifestations in Autoimmune Lymphoproliferative Syndrome and Autoimmune Lymphoproliferative Syndrome-like Disorders.
Failing C; Blase JR; Walkovich K
Rheum Dis Clin North Am; 2023 Nov; 49(4):841-860. PubMed ID: 37821199
[TBL] [Abstract][Full Text] [Related]
32. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane.
Siegel RM; Muppidi JR; Sarker M; Lobito A; Jen M; Martin D; Straus SE; Lenardo MJ
J Cell Biol; 2004 Nov; 167(4):735-44. PubMed ID: 15557123
[TBL] [Abstract][Full Text] [Related]
33. What's up in the ALPS.
Rieux-Laucat F
Curr Opin Immunol; 2017 Dec; 49():79-86. PubMed ID: 29073495
[TBL] [Abstract][Full Text] [Related]
34. Autoimmune lymphoproliferative syndrome with somatic Fas mutations.
Holzelova E; Vonarbourg C; Stolzenberg MC; Arkwright PD; Selz F; Prieur AM; Blanche S; Bartunkova J; Vilmer E; Fischer A; Le Deist F; Rieux-Laucat F
N Engl J Med; 2004 Sep; 351(14):1409-18. PubMed ID: 15459302
[TBL] [Abstract][Full Text] [Related]
35. Childhood polyarteritis nodosa in autoimmune lymphoproliferative syndrome.
Naumann-Bartsch N; Stachel D; Morhart P; Staatz G; Jüngert J; Schwarz K; Holter W
Pediatrics; 2010 Jan; 125(1):e169-73. PubMed ID: 20026502
[TBL] [Abstract][Full Text] [Related]
36. HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia).
Vacek MM; Schäffer AA; Davis J; Fischer RE; Dale JK; Adams S; Straus SE; Puck JM
Clin Immunol; 2006 Jan; 118(1):59-65. PubMed ID: 16257267
[TBL] [Abstract][Full Text] [Related]
37. ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies.
Consonni F; Gambineri E; Favre C
Ann Hematol; 2022 Mar; 101(3):469-484. PubMed ID: 35059842
[TBL] [Abstract][Full Text] [Related]
38. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.
Nabhani S; Ginzel S; Miskin H; Revel-Vilk S; Harlev D; Fleckenstein B; Hönscheid A; Oommen PT; Kuhlen M; Thiele R; Laws HJ; Borkhardt A; Stepensky P; Fischer U
Haematologica; 2015 Sep; 100(9):1189-98. PubMed ID: 26113417
[TBL] [Abstract][Full Text] [Related]
39. New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome.
Teachey DT
Curr Opin Pediatr; 2012 Feb; 24(1):1-8. PubMed ID: 22157362
[TBL] [Abstract][Full Text] [Related]
40. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.
Dowdell KC; Niemela JE; Price S; Davis J; Hornung RL; Oliveira JB; Puck JM; Jaffe ES; Pittaluga S; Cohen JI; Fleisher TA; Rao VK
Blood; 2010 Jun; 115(25):5164-9. PubMed ID: 20360470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
